x/a carbohydrates, ligands for E-selectin, correlates with clinically advanced stages and metastasis of gastric and colon cancers. In contrast, Sd a carbohydrate is abundantly detected in the normal gastrointestinal mucosa but dramatically reduced or lost in cancer tissues. A glycosyltransferase, β1,4N-acetylgalactosaminyltransferase 2 (B4GALNT2) that catalyzes Sd a carbohydrate synthesis, is silenced in cancer. In the present study, we aimed at reducing the expression of sialyl Lewis x/a of cancer cells in vivo by forced expression of B4GALNT2 and Sd a , thereby preventing dissemination/metastasis, especially metastasis triggered by surgical maneuvers. We used a fiber-modified adenovirus (Ad) vector that contained a chimeric construct with a serotype 5 shaft and a serotype 3 knob. Using this Ad5/3 vector, we successfully introduced the B4GALNT2 gene into a human gastric cancer cell line KATO III in vitro and confirmed replacement of sialyl Lewis x to Sd a with a decrease in E-selectindependent adhesion. Administration of Ad5/3-B4GALNT2 vectors into the peritoneal cavity of mice after inoculation of KATO III cells with laparotomy significantly reduced the incidence of metastasis. Our results indicate that the transfer of a single gene encoding B4GALNT2 modified carbohydrate chains of cancer cells in vivo and decreased tumor dissemination and metastasis.
INTRODUCTION
It has been known that malignant transformation is associated with abnormal expression of carbohydrate determinants. 1, 2 In these altered carbohydrate structures, significant correlations between the postoperative prognosis of the patients and the degree of expression of the sialyl Lewis x/a (NeuAcα2-3Galβ1-4/3 (Fucα1-3/4)GlcNAc-R) in cancer tissues have been shown for both colon and stomach cancers. [3] [4] [5] Further, sialyl Lewis x and sialyl Lewis a determinants in cancer cells serve as ligands for E-selectin, which is inducibly expressed by endothelial cells and functions as a cell adhesion molecule. 6, 7 Thus, interactions between E-selectin and its specific carbohydrate ligands have a significant role in hematogenous metastasis. On the other hand, the blood group Sd a carbohydrate, which is GalNAcβ1-4(NeuAcα2-3)Galβ1-4GlcNAc, is abundantly expressed on glycolipids and glycoproteins in the normal gastrointestinal mucosa in the majority of humans. [8] [9] [10] An important characteristic of this carbohydrate determinant is that its expression in cancer tissue is strikingly reduced or absent. The last step in the biosynthesis of Sd a is catalyzed by β1,4-N-acetylgalactosaminyltransferase 2 (B4GALNT2). [11] [12] [13] The substrate sugar acceptor NeuAcα2-3Galβ1-4/3GlcNAc-R for this reaction is the same as the one used for the last step of sialyl Lewis x/a synthesis, which is catalyzed by fucosyltransferases. Thus synthetic pathways of Sd a and sialyl Lewis x/a compete their substrate. Recent report showed that the expression of B4GALNT2 cooperates with fucosyltransferase FUT6 in determining the level of sialyl Lewis x in normal colonic mucosa. 14 The enzyme activity of the B4GALNT2 responsible for synthesizing the Sd a determinant dramatically decreases in gastric and colonic cancer tissues. 15, 16 Therefore increased level of sialyl Lewis x/a in cancer tissues may be likely due to increase of substrate acceptors available for sialyl Lewis x/a synthases in concordance with decreased expression of B4GALNT2. Indeed, we found that DNA hypermethylation of B4GALNT2 gene in cancer tissue caused silencing of this enzyme expression and activity associated with loss of Sd a carbohydrate structure. 17 Further, we demonstrated that forced expression of B4GALNT2 in gastrointestinal cancer cells reduced their expression of sialyl Lewis x/a carbohydrates and decreased their metastatic potential in nude mice. 18 Similar effect on surface carbohydrate was confirmed by other group using colon cancer cell lines with forced expression of B4GALNT2 in vitro experimental system. 19 These results strongly suggest the therapeutic potential of B4GALNT2 gene transfer to prevent E-selectin-mediated tumor metastasis. However, to our knowledge, there is no report of in vivo therapeutic transfer of B4GALNT2 gene aiming the prevention of metastasis. To accomplish the effective gene transfer into gastrointestinal cancer cells, we used a fiber-modified adenovirus (Ad) vector containing a chimeric construct with a serotype 5 shaft and a serotype 3 knob (Ad5/3). 20 We thought that targeting the surgery-driven tumor metastasis 21 would be suitable to apply this gene therapy. To evaluate the effect of the gene transfer, we established surgerytriggered metastasis model in mice and attempted to control sialyl Lewis x expression of cancer cells by in vivo transfer of the B4GALNT2 gene and thereby to prevent metastasis.
MATERIALS AND METHODS

Mice, cells and reagents
Six-to-eight-week-old male athymic BALB/c nude (nu/nu) mice were purchased from Japan SLC (Hamamatsu, Shizuoka, Japan) and maintained under pathogen-free conditions in the animal facility of the National Center for Global Health and Medicine (NCGM 23 were both provided from Tokyo Research Park, Kyowa Hakko Kirin, Tokyo, Japan.
Viruses. Ad5/3-Luc, a chimeric Ad5 vector having Ad3 tropism, was generated by substitution of the Ad3 knob domain into the Ad5 fiber protein. 20 AdRGD-Luc, which contains an integrin-binding motif (RGD) inserted in the HI loop of the fiber knob region, was described previously. Ad5-Luc, AdRGD-Luc and Ad5/3-Luc viruses are E1
− replication-defective Ad vectors with a cytomegalovirus promoter-driven luciferase reporter gene inserted into their E1 region. The viruses were propagated in 293 cells and purified by double centrifugation on cesium chloride gradients by using standard methods. The viral particle (vp) concentration was determined by spectrophotometric measurement at an absorbance of 260 nm, where 1 absorbance unit is equivalent to 1.1 × 10 12 vp ml − 1 .
Construction of Ad5/3-B4GALNT2. We had previously cloned a cDNA containing the full-length open reading frame of the human B4GALNT2 gene. 18 The B4GALNT2 cDNA had been subcloned into a pShuttle cytomegalovirus vector (Quantum Biotechnologies, Montreal, Quebec, Canada). Homologous recombination with the Ad5/3 backbone vector resulted in plasmid Ad5/3-B4GALNT2, which contained the recombinant Ad genomes. Replication-deficient, E1-deleted Ad5/3-B4GALNT2 particles were amplified in 293 cells.
Assay for luciferase expression. Cells were infected (500 vp cell − 1 ) with the Ad5-Luc or fiber-knob-modified AdRGD-Luc or Ad5/3-Luc vector. Four days after infection, the cells were lysed with luciferase cell culture lysis reagent (Promega, Madison, WI, USA) and assayed for luciferase expression.
Assay of mRNA expression of B4GALNT2. Total RNA was isolated from tissues using RNeasy Mini Kit (QIAGEN, Hilden, Germany). After the RNA was treated with DNase I, double-stranded cDNA was synthesized and subjected for PCR to discriminate two isoforms of the B4GALNT2, known as the short form and the long form, using two sets of primers specific for each isoform. PCR primer pairs used in this study were 5′-CTGAGGG CGGCGGGATTCGGGATGAC-3′/5′-GAGGTCGCTCTGGCCATAGGCA-3′ (specific for a short form) and 5′-GTGGCCTCTCGCGGCCGGGAATG-3′/5′-CACA TTTGCACTGATTTTTCG-3′ (specific for a long form). PCR products (size 323 and 388 bp, respectively) were detected with electrophoresis. Quantitative PCR was performed using ABI TaqMan probes (Applied Biosystems, Tokyo, Japan) as described previously. Threshold cycle numbers were determined running 40 cycles using the Sequence Detector software and transformed as described by the manufacturer (Applied Biosystems). The TaqMan Geneexpression assay ID used in this study for human B4GALNT2 and human glyceraldehyde-3-phosphate dehydrogenase was Hs00396440_m1 and 4310884E, respectively.
Assay of B4GALNT2 activity. The lysates of Ad5/3-B4GALNT2-infected KATO III cells (1 × 10 7 ) were examined for enzyme activity as described previously 25 by using pyridylaminated α2,3sialyllactose as an acceptor.
Flow cytometry. Flow cytometry was performed with a FACScan (BD Bioscience, Palo Alto, CA, USA). Cells were stained with the mouse monoclonal antibodies indicated as above, biotin-conjugated horse anti-mouse Ig (Vector Laboratories, Burlingame, CA, USA) and PE-conjugated streptavidin (BD PharMingen, San Diego, CA, USA).
Cell adhesion assays. To evaluate the E-selectin-dependent cell adhesion, we used CHO cells stably expressing human E-selectin, as previously described. 18 Briefly, infected KATO III cells were labeled with 3′-O-acetyl-2′,7′-bis(carboxyethyl)-4 or 5-carboxyfluorescein diacetoxymethlester and were placed in wells containing a monolayer of CHO or CHO-E-selectin cells. After incubation, the wells were washed to remove unattached cells, and then the attached cells were lysed in 1% Triton X-100 at 37°C. The fluorescence intensity of the lysates was assessed with a fluorometer (Fluoroskan Ascent FL, Dainippon Sumitomo Pharma, Osaka, Japan).
In vivo metastasis assay. Exponentially growing KATO III cells were harvested and suspended in Hank's balanced salt solution. Suspensions of KATO III cells (1 × 10 7 ) were inoculated into the peritoneal cavity of individual male athymic mice. To model peritoneal dissemination and metastasis at surgical treatment, each mice was anesthetized with ketamine and xylazine, and a midline incisions at the area 5 mm apart from xiphoid process and 15 mm long was made. Cancer cell suspension was injected through this incision, and abdominal wall was closed with five sutures. Immediately after this, the mice were intraperitoneally administered with Ad5/3-B4GALNT2 or Ad5/3-mock (without cDNA) at the dose of 1 × 10 10 vp per mouse with a needle and syringe. Twelve weeks later, the mice were killed, and their tumor lesions were microscopically examined. In some experiments, cells were collected from the peritoneal cavities of the mice 3 days after infection. The peritoneal cell fraction including the majority of gastric cancer cells were gated by size of the cultured cells and were analyzed for their carbohydrate expression by flow cytometry.
Statistics. Data were expressed as the mean ± one s.d., and the results were compared by the two-tailed, unpaired Mann-Whitney, Student t-test or χ 2 test by using the Statview II statistical program (Abacus Concepts, Berkeley, CA, USA).
RESULTS
Efficiency of infection of human gastrointestinal cancer cells by fiber-knob-modified Ad vectors
We previously found that the introduction of Sd a carbohydrate into gastrointestinal cancer cells by the forced expression of B4GALNT2 eliminated their expression of sialyl Lewis x/a and eventually decreased selectin-mediated metastasis. With the final aim of therapeutic transfer of the B4GALNT2 gene in vivo, we examined the reporter gene expression in human gastrointestinal cancer cells after having infected them with Ad-Luc vectors in vitro to determine the infectious efficiency. As reported previously, the vector of serotype 5 normal-version Ad (Ad5), which is generally used for Ad gene delivery, showed low infectivity toward both human gastric cancer KATO III and colorectal cancer HT29 cells, probably due to their poor expression of CAR, the native Ad5 receptor (Figure 1 ). To accomplish the effective gene transfer into gastrointestinal cancer cells, we used two different fiber-modified Ad vectors: AdRGD, having the Arg-Gly-Asp (RGD) motif incorporated into the fiber knob, and Ad5/3, containing the chimeric construct with a serotype 5 shaft and a serotype 3 knob. 24, 26 The Ad5/3 vectors afforded 10-20 times greater gene delivery to both KATO III and HT29 cells in comparison with unmodified or RGDmodified vectors (Figure 1 ). Based on these results, we chose the Ad5/3 vector to introduce the B4GALNT2 gene into gastric cancer cells in vivo.
Selection of long protein isoform of B4GALNT2 for Ad-mediated gene transfer Transcription of the B4GALNT2 gene produces at least two isoforms, a 566 amino acid long form and a 506 amino acid short form, 14 as has extensively been reviewed recently. 10 Both isoforms are able to synthesize the Sd a determinant 19 but may differ regarding competition with fucosyltransferases and suppression of sialyl Lewis x . Initially, we analyzed the expression of the long and short B4GALNT2 isoforms in several cancer cell lines. We found that KATO III and HT29 cells did not express either isoform, whereas renal cell carcinoma TOS-1 cells expressed the short form but not the long form (Figure 2a Ad-mediated transfer of B4GALNT2 gene promoted enzymatically active glycosyltransferase and modulated cell attachment to E-selectin When KATO III cells were infected with the Ad5/3 vector bearing the cytomegalovirus promoter-driven B4GALNT2 gene in vitro, the homogenates of the cells transferred N-acetylgalactosamine at high efficiency to α2,3sialyllactose. B4GALNT2 activity was hardly detected in either uninfected or Ad5/3-mock-infected KATO III cells ( Figure 3a) . As sialyl Lewis x on the cancer cell surface functions as a ligand for E-selectin, 3, 7 we next examined the effects of Ad-mediated transfer of the B4GALNT2 gene on E-selectin-dependent cell adhesion. In contrast to strong adhesion of Ad5/3-mock-infected KATO III cells to E-selectin-expressing CHO cells, adhesion of Ad5/3-B4GALNT2-infected KATO III cells were significantly weak (Figure 3b) . These results clearly show that the transfer of the B4GALNT2 gene into cancer cells abolished their E-selectin-dependent adhesion in vitro.
Inhibition of metastasis by Ad-mediated transfer of B4GALNT2 gene in vivo Next we evaluated the therapeutic effects of Ad-mediated transfer of the B4GALNT2 gene in vivo by using a mouse peritoneal metastatic model. Initially, we injected KATO III suspension intraperitoneally with a needle to form metastatic foci; 18 however, we noticed that in cleaner condition of animal facility this method often failed to induce metastatic focus in any organ. Because surgery is known to trigger metastasis, 21 we performed laparotomy with a large incision at tumor cell inoculation and found it an efficient and reliable method to induce metastasis. This treatment resulted in consistent formation of metastatic foci in the spleen, liver, peritoneum and seminal vesicles. When Ad5/3-B4GALNT2 viruses were delivered into the peritoneal cavity immediately after inoculation of KATO III cells, the incidence of metastasis was significantly reduced compared with the administration of Ad5/3-mock viruses (Table 1 and Figure 4a ). There was no statistically significant difference in the incidence of metastasis between untreated and Ad5/3-mock-treated mice. To examine the expression of the transferred gene in KATO III cells in vivo, we collected cells from the peritoneal cavities of mice 3 days after the administration of Ad5/3 viruses. We confirmed much increased mRNA expression of B4GALNT2 in KATOIII-injected Ad5/3-B4GALNT2-administered mice as compared with KATOIII-injected Ad5/3-mock-administered mice (Figure 4b ). To determine the induced expression of Sd a in injected KATO III cells distinguishing from murine leukocytes, cells recovered from murine peritoneal cavities were stained with anti-murine CD45 and anti-Sd a antibody. Without KATO III injection, all cells collected from peritoneal cavity expressed mouse CD45 and some of them reacted with anti-Sd a antibody, which are likely mouse hematopoietic cells expressing CT oligosaccharide 27 ( Figure 4c ). In contrast, most CD45-negative cells recovered from Ad5/3-B4GALNT2-administered mice after KATO III injection expressed Sd a carbohydrate determinant, but Ad5/3-mock-administered mice did not (Figures 4c and d) . This result clearly indicated that B4GALNT2 was induced by mouse CD45-negative KATO III cells in vivo. Of note, the expression of sialyl Lewis x was remarkably suppressed in peritoneal cell fraction including the majority of tumor cells collected from Ad5/3-B4GALNT2-treated mice compared with its expression in uninfected KATO III cells or in the tumor cells from Ad5/3-mock-administered mice (Figure 4d ). The altered expression of these carbohydrate determinants in KATO III cells was the same as that seen after Ad-mediated transfer of the B4GALNT2 gene in vitro, clearly suggesting that the efficient transfer of this gene significantly inhibited tumor metastasis of sialyl Lewis x -positive gastric cancer cells. There was no difference Abbreviations: Ad, adenovirus; B4GALNT2, β1,4-N-acetylgalactosaminyltransferase 2. Statistically significant when compared with Ad5/3-mock-administered mice (*P = 0.01 and **P = 0.003).
a Multiple organ metastases were assessed by using nude mice administered the indicated Ad viruses immediately after intraperitoneal injection of KATO III cells. in the number of cells recovered from Ad5/3-mock or Ad5/3-B4GALNT2-treated mice at this time point.
DISCUSSION
There are significant correlations between the degree of expression of sialyl Lewis x/a determinants in cancer tissues and the postoperative prognosis of patients with colon, lung, breast, stomach, prostate and urinary bladder cancers. [3] [4] [5] [28] [29] [30] Therefore elimination of the sialyl Lewis x/a determinants from cancer cells has been an important goal for the control of cancer metastasis.
Many glycosyltransferases, such as α2,3 sialyltransferases and α1,3/4 fucosyltransferases of several molecular species, participate in the complete biosynthesis of sialyl Lewis x and sialyl Lewis a ; and apparently, the final expression levels of sialyl Lewis x/a epitopes are not controlled by a single glycosyltransferase but through a combinatorial effect of multiple glycosyltransferases. In light of this situation, the inhibition of a certain glycosyltransferase activity in the biosynthetic pathway of sialyl Lewis x/a would not be an effective way for elimination of sialyl Lewis x/a in human cancers. The present study provides the evidence that efficient delivery of the gene for a single glycosyltransferase, B4GALNT2, has the therapeutic potential for selectin-mediated tumor metastasis by reducing the expression of the ligand of selectin. This therapeutic effect observed in gastric cancer would be expected to be seen in any type of cancer cells that express high levels of sialyl Lewis x/a , irrespective of the underlying mechanism for their expression. Furthermore, for gene therapy, it is a great advantage that introducing a single gene for a single enzyme is able to alter the expression of functional carbohydrates dramatically whose expression is actually under multifactorial control.
For achieving the most effective prevention of metastasis, a concern is the timing when therapeutic procedures should be done. For example, peritoneal metastasis accounts for 40-60% of the recurrence after curative surgery in gastric cancer patients; and it has been reported that the optimal target for antimetastatic therapy against the peritoneal recurrence of gastric cancer is the tumor cells that disseminate into the peritoneal cavity immediately after surgery. 31 However, the results of treatment such as combination chemotherapy and chemohyperthermia are still unsatisfactory. In our clinically relevant peritoneal metastasis model of surgery, single administration of a B4GALNT2 gene exhibited an inhibitory effect on gastric cancer metastasis. This fact suggests that interactions between E-selectin and its specific carbohydrate ligands function at a very early stage of the metastatic focus formation is critical. Therefore, we speculate that transient gene expression with an Ad vector would be sufficient to show a curative effect. Thus, Ad-mediated transfer of the B4GALNT2 gene immediately after surgery would be one of the most effective remedies to reduce the risk of gastric cancer metastasis.
Another issue in the application of this gene therapy is that biological function of Sd a carbohydrate induced in cancer cells or other cell types is not clear yet. In our previous study, forced expression of B4GALNT2 in intraperitoneal tumor cells did not affect their growth or viability, 18 suggesting that this gene product is not, at least, cytotoxic. Indeed, we found that tumor cells survived at least 3 days after inoculation and that there was no difference in their survival between Ad5/3-mock-infected and Ad5/3-B4GALNT2-infected cells in vivo. These results also indicate that the inhibitory effect on cancer metastasis by the gene delivery of B4GALNT2 is not due to growth inhibition. On the other hand, in the case of mouse melanoma, recent report showed that melanoma cells with relatively high expression of β4-galactosyltransferase 2 (β4GalT2) gene formed smaller tumor after subcutaneous inoculation than control cells, and direct Ad gene delivery of β4GalT2 to hepatocellular carcinoma subcutaneously grown in SCID mice reduced its size, 32 suggesting that adenoviral introduction of a glycosyltransferase which synthesizes N-acetyllactosamine may modify cell growth. In our gastric cancer peritoneal metastasis, disseminated tumor cells are known to be on the omentum, where peritoneal macrophages reside, in the initial proliferative phase. As mouse peritoneal macrophages are known to express P-selectin, as do platelets and endothelial cells, 33 disseminated tumor cells may use peritoneal macrophages activated by surgical stress as anchors for adhesion and further proliferation. This interaction may eventually facilitate the hematogenous metastasis of tumor cells, and so our therapeutic approach might prevent such tumor cell-peritoneal macrophage interaction. As peritoneal macrophages and peritoneal mesothelial cells were activated immediately after surgical injury in our mouse model through the reaction with chemokines, 34, 35 preventive administration of Ad5/3-B4GALNT2 viruses at the time of curative surgery in sialyl Lewis x/a -positive gastric cancer patients might be very effective and applicable as an adjunct to current therapy. For this application, we certainly need to have better knowledge about the biological functions of B4GALNT2 protein and Sd a carbohydrate in not only cancer cells but also in other cell types such as leukocytes to predict possible adverse effects of the forced expression of Sd a in vivo. However, for this purpose, information
we can obtain from human cancer in mouse model is limited. Therefore, as a next step, we are planning in vitro infection of human peritoneal lavage cells with Ad5/3-B4GALNT2 to investigate the expression of Sd a and selectin ligands of various cell types with their possible alteration of cellular functions.
